Retatrutide and MT2 on TikTok: separating hype from human data

What did @imnotmoosee actually say?

The creator defended their peptide use against skeptics and credited an app called PepAI for sorting out their dosing. Their words: "the only reason I dose my peptides correctly now is because of the Pepe I app." They also claim they were once taking "nine peptides a day" and previously relied heavily on a compound they called "red" (likely retatrutide, based on the hashtag #reta). The needle-fear jab at critics is mostly posturing, but the underlying message is real: they were running a complex, self-directed peptide stack and found the volume unmanageable without help. That part, at least, is plausible. Peptide stacks at that scale are not uncommon in online biohacking communities, and the dosing complexity is genuinely significant. Nine peptides simultaneously would involve multiple injection sites, different reconstitution volumes, varying half-lives, and real risk of compounding errors.

Does the science back this up?

The science on individual peptides is mixed, and the evidence for stacking nine of them simultaneously is essentially nonexistent. Let's be direct about that. For some peptides like BPC-157, there is animal data suggesting accelerating tissue repair, but human randomized controlled trial data remains thin. Sikiric et al. (2018, Current Pharmaceutical Design) reviewed BPC-157's gastrointestinal and systemic effects in rodents and found promising signals, but acknowledged the jump to human clinical application is not yet supported by robust trials. Retatrutide, referenced via the #reta hashtag, is a triple agonist (GIP, GLP-1, GLP-2 receptors) that Eli Lilly has studied in Phase 2 trials. Jastreboff et al. (2023, New England Journal of Medicine) reported significant weight reduction in obese adults, but that was pharmaceutical-grade retatrutide in a controlled setting, not a compounded version self-administered by a TikToker. The creator's implication that these compounds are interchangeable with clinical-grade drugs is not supported.

What did they get wrong (or right)?

They got one thing right: dosing complexity in multi-peptide protocols is a genuine problem. When you are managing compounds with different reconstitution requirements, injection frequencies, and storage conditions, errors happen. An app that helps track that is not an absurd idea. However, the creator implies that correct dosing alone legitimizes a nine-peptide stack, and that is a real logical leap. Correct dosing of the wrong combination is still potentially risky. The hashtag inclusion of #mt2 (Melanotan II) is worth flagging separately. Melanotan II is not approved by the FDA for any indication, has been associated with serious adverse events including melanocytic changes and cardiovascular effects (Evans-Brown et al., 2009, British Journal of Clinical Pharmacology), and is not something an app "correctly dosing" makes safe. The creator also dismisses critics as simply "scared of the needle," which sidesteps legitimate safety concerns that have nothing to do with needle phobia.

What should you actually know?

Running a self-directed peptide stack sourced outside a regulated medical framework carries real risks that enthusiasm and a tracking app do not eliminate. Compounded peptides vary in purity, and there is no standardized quality assurance across suppliers. The FDA has issued multiple warnings about compounded peptides, and several, including BPC-157 and TB-500, have been placed on the FDA's list of peptides that may not be compounded for human use. Beyond sourcing, polypharmacy at this scale, nine concurrent compounds, means interactions are genuinely unknown. There are no human studies examining what happens when you combine GHK-Cu, BPC-157, ipamorelin, CJC-1295, and Melanotan II simultaneously. "I dose correctly" is not the same as "this is safe." If you are curious about peptide therapy, the correct pathway is through a licensed provider who can evaluate your individual health status and prescribe regulated compounds with documented quality controls, not a TikTok stack validated by an AI app.

Bottom line on the PepAI app claim

Crediting an app for fixing your dosing chaos is not inherently wrong. If the app helped organize injection schedules, track vial usage, and reduce calculation errors, that has real utility. Dosing errors in injectable compounds are a legitimate patient safety issue. But an app is a logistics tool, not a clinical safeguard. It cannot screen for contraindications, flag dangerous combinations, or confirm that what you ordered from an online supplier matches its label. The creator presents app-assisted dosing as the solution to a complex medical self-experiment. It is, at best, a small organizational piece of a much larger safety puzzle they do not appear to have solved.